Is BPC-157 Legal in Texas?

The Short Answer on BPC-157 and Texas Law

Texas does not have a standalone statute that places BPC-157 on a prohibited-substances list. The legal complexity comes entirely from federal law, specifically the Federal Food, Drug, and Cosmetic Act (FD&C Act) and FDA's evolving guidance on bulk drug substances used in compounding. Because BPC-157 has not cleared any FDA approval pathway, any preparation intended for human use must manage compounding law carefully or it becomes an unapproved new drug in the eyes of federal regulators.

The Texas State Board of Pharmacy (TSBP) enforces both Texas pharmacy statutes and mirrors applicable federal standards. A compounding pharmacy operating in Texas cannot legally produce BPC-157 for human use in ways that conflict with FDA's bulk-substances guidance without exposing its license to risk.

Why No Single Law Gives a Clean Yes or No

Regulatory status for unapproved peptides does not follow a simple binary. FDA has authority over drugs in interstate commerce under 21 U.S.C. § 301 et seq. Texas has authority over pharmacy practice and medical licensing within its borders. Neither body has issued a criminal prohibition specific to BPC-157 possession by an individual. The restriction lands on manufacturers, compounders, and dispensers, not on patients holding a vial.

That distinction matters clinically. A patient in Austin who has a compounded preparation dispensed under a valid prescription is in a different legal position than a person ordering raw BPC-157 powder online and reconstituting it at home.

Federal Framework: FDA's Bulk Drug Substances Lists

Understanding BPC-157's status requires understanding how FDA classifies bulk drug substances used in compounding. Under sections 503A and 503B of the FD&C Act, pharmacies and outsourcing facilities may compound using bulk substances only under specific conditions. FDA maintains two separate lists for each pathway. FDA guidance on compounding is the controlling document.

The 503A Pathway (Traditional Compounding Pharmacies)

Section 503A covers traditional pharmacies that compound for individual patients based on a valid prescription. These pharmacies may use bulk substances that are:

• Included on FDA's 503A bulks list (Category 1), or
• Components of an FDA-approved drug, or
• On the United States Pharmacopeia (USP) or National Formulary (NF) list.

BPC-157 does not appear on the FDA-approved 503A Category 1 list. FDA has evaluated it and placed it in a category that signals significant concern about safety or lack of clinical evidence. Pharmacies compounding BPC-157 under 503A therefore operate without FDA's explicit authorization for that substance, which creates enforcement exposure.

The 503B Pathway (Outsourcing Facilities)

Section 503B outsourcing facilities can compound without individual prescriptions and supply healthcare facilities, but only using substances on FDA's 503B bulks list or FDA-approved drug components. BPC-157 is not on the approved 503B bulks list, and FDA's interim policy documents make clear that outsourcing facilities may not use substances under evaluation that have not received a positive determination. This effectively closes the 503B door for BPC-157 under current guidance.

FDA's Category 2 Designation

FDA's Category 2 bulks list identifies substances nominated for the 503A list that the agency has reviewed and for which it has significant concerns, either about safety, evidence of effectiveness, or both. BPC-157 has been identified in this context. A 2023 FDA document outlines the review process and notes that substances with insufficient clinical evidence or safety data may be denied listing. BPC-157's near-complete absence of human clinical trial data is a key driver of that concern.

Texas State Law: What TSBP and the Medical Practice Act Actually Say

Texas regulates pharmacy practice through the Texas Pharmacy Act (Texas Occupations Code, Chapter 558 and related provisions) and the Texas Medical Practice Act (Chapter 151-165). Neither act names BPC-157 explicitly. TSBP rules require that all compounded preparations meet applicable federal and state standards, which means TSBP enforcement piggybacks on FDA's federal framework.

Texas Medical Practice Act and Prescribing Authority

A Texas-licensed physician retains broad authority to prescribe any substance for a patient when supported by sound medical judgment, so long as that substance is not federally scheduled and the prescription reflects a legitimate physician-patient relationship. This is the same authority that supports off-label prescribing of FDA-approved drugs. BPC-157 is not a scheduled substance under the DEA's Controlled Substances Act schedules, confirmed by the DEA's controlled-substances list.

What a Texas physician cannot do is direct a 503B outsourcing facility to produce BPC-157, because that facility has no lawful authority to use the substance. A physician working with a 503A compounding pharmacy faces a narrower but still possible pathway, with the caveat that the pharmacy assumes the legal and licensure risk.

Texas Department of State Health Services

DSHS does not maintain a separate peptide-prohibition list. Its controlled-substances schedules track federal DEA schedules closely, and BPC-157 does not appear on any of them. Possession of BPC-157 by an individual in Texas is not a criminal offense under Texas Health and Safety Code Chapter 481 (the Texas Controlled Substances Act).

A Practical Regulatory Tier Map for Texas Patients

To make the overlapping rules navigable, consider this three-tier view:

Tier 1: Clearly permissible. A Texas physician issues a patient-specific prescription. A Texas-licensed 503A compounding pharmacy, after independently assessing its own legal exposure under federal compounding law, dispenses a compounded BPC-157 preparation. The patient uses it under medical supervision.

Tier 2: Gray area with real risk. A compounding pharmacy produces BPC-157 in bulk or for office stock without individual prescriptions. This conflicts with both 503A (which requires patient-specific scripts) and 503B restrictions. The pharmacy bears the enforcement risk.

Tier 3: Not legally defensible for human use. A vendor sells BPC-157 powder or solution labeled or marketed for human administration without involving a licensed prescriber or compounder. This triggers FD&C Act violations on the seller's side. The buyer may face no criminal charge, but the product has no quality or dosing assurance.

The Evidence Gap That Drives FDA's Caution

FDA's reluctance to list BPC-157 on the approved 503A bulks schedule is grounded in the evidence base, which is almost entirely preclinical. BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a sequence found in human gastric juice. Animal studies, primarily in rats, have reported effects on wound healing, tendon repair, and gastric mucosa protection. A 2018 review in Current Pharmaceutical Design summarized these findings but noted the absence of controlled human trials.

No Phase III randomized controlled trial of BPC-157 in humans has been published as of early 2025. ClinicalTrials.gov lists a small number of early-phase investigations, none of which have produced peer-reviewed efficacy or safety data sufficient to support FDA approval or compounding-list inclusion.

What the Animal Data Actually Shows

Rat and rodent studies have reported accelerated healing of Achilles tendon transections, reduced gastric ulcer size, and modulated nitric oxide signaling. A 2021 paper in Biomedicines found that BPC-157 reduced inflammation markers in a rodent model of inflammatory bowel disease. These are hypothesis-generating findings. They do not establish human dosing, safety profiles, pharmacokinetics in humans, or long-term toxicology data.

FDA's guidance on bulk-substance nominations explicitly requires "adequate evidence that the substance is safe and effective" for its intended use. Animal studies alone do not satisfy that threshold, which is why BPC-157 has not cleared the 503A review.

Absence of Human Pharmacokinetic Data

Human pharmacokinetic data for BPC-157, covering absorption, distribution, metabolism, and excretion in people, does not exist in published peer-reviewed literature as of this writing. Without that data, a prescribing physician cannot anchor dosing to an evidence-based target. The typical self-administration protocols circulating in online communities (250 to 500 mcg subcutaneously or intramuscularly once or twice daily) are derived from rat-dose extrapolations, not human trials.

How to Get BPC-157 in Texas: The Legitimate Pathway

The only pathway that avoids federal law violations for a Texas resident seeking BPC-157 for personal use involves three sequential steps.

Step 1: Establish Care with a Licensed Texas Physician

The physician must conduct a proper evaluation, document a clinical rationale, and issue a patient-specific prescription. Telehealth is permitted in Texas under the Texas Medical Practice Act, and the Texas Medical Board has affirmed that telemedicine visits satisfy the physician-patient relationship requirement, provided the standard of care is met. The Texas Medical Board's telemedicine rules confirm this.

Step 2: Identify a 503A Compounding Pharmacy Willing to Fill the Prescription

Not all compounding pharmacies in Texas will fill BPC-157 prescriptions. A pharmacy that does must make its own determination about compliance with federal compounding rules and accept the associated risk. The pharmacist has an independent duty to verify that the prescription is valid and that the preparation meets applicable standards under USP <795> for non-sterile or USP <797> for sterile preparations.

Sterile injectable preparations of BPC-157 fall under USP <797> standards. That chapter sets strict requirements for beyond-use dating, environmental monitoring, and personnel training. A pharmacy cutting corners on sterile compounding creates safety risks that go beyond the regulatory question.

Step 3: Use Under Medical Supervision

A physician prescribing an off-label or investigational compound bears an obligation to monitor the patient. Liver function, renal function, and any adverse events should be tracked. There is no FDA-approved monitoring protocol because there is no approved drug, but standard-of-care principles still apply and are enforceable under the Texas Medical Practice Act.

Buying BPC-157 Online: Research Chemical Vendors

A large portion of BPC-157 sold in the United States moves through "research chemical" vendors who label products "not for human use" or "for laboratory research only." These labels are legal workarounds. The product is identical to what compounding pharmacies produce, but it has undergone no pharmaceutical-grade quality testing, no sterility assurance, and no potency verification by a licensed facility.

Purchasing BPC-157 from these vendors for personal injection is not a criminal act in Texas (no statute prohibits it), but it bypasses every quality safeguard that compounding law exists to provide. A 2021 FDA warning letter to peptide vendors cited precisely this labeling scheme as a violation of the FD&C Act on the seller's side.

The risk to the buyer is medical rather than legal: unknown purity, unknown potency, bacterial contamination from non-sterile lyophilization, and no recourse if harm results.

BPC-157 and FDA Enforcement Trends

FDA enforcement against peptide compounders and vendors has intensified since 2020. The agency sent warning letters to multiple compounding pharmacies and online sellers offering BPC-157, TB-500, and similar peptides. A 2023 FDA statement on compounded drugs reiterated that compounding bulk substances not on an approved list is not permissible for 503B outsourcing facilities.

The practical effect in Texas has been that some compounding pharmacies stopped offering BPC-157 after 2022 to avoid federal scrutiny. Others continue under the 503A individual-prescription model, accepting that the legal question is unsettled rather than clearly resolved in their favor.

The Endocrine Society's position on off-label compounded peptides, summarized in a 2023 commentary in the Journal of Clinical Endocrinology and Metabolism, notes that "the compounding of substances with inadequate clinical evidence creates both patient safety concerns and regulatory ambiguity that clinicians should communicate clearly to patients." That framing captures the BPC-157 situation precisely.

Comparing BPC-157 to Other Peptides in Texas

Context helps. Semaglutide (Ozempic, Wegovy) is an FDA-approved peptide drug. During the FDA-declared shortage period, compounding of semaglutide was permitted for 503A and 503B facilities under specific conditions. The FDA shortage compounding guidance provided a defined legal basis. BPC-157 has no equivalent shortage or approval basis.

Sermorelin is another compounded peptide. Unlike BPC-157, sermorelin was once FDA-approved (Geref), which means a known safety and pharmacokinetic profile exists. FDA allows its compounding under certain conditions for that reason. BPC-157 has never been FDA-approved for any indication, which removes that historical anchor.

This comparison illustrates that the barrier to BPC-157 compounding is not ideological opposition to peptides. It is the specific absence of the human safety and efficacy data that compounding law requires.

Physician Liability and Informed Consent in Texas

A Texas physician prescribing BPC-157 should provide written informed consent that addresses several points: the absence of FDA approval, the lack of human pharmacokinetic data, the animal-only evidence base, the potential for unknown adverse effects, and the non-standard nature of the preparation. The Texas Medical Liability Act (Chapter 74, Texas Civil Practice and Remedies Code) governs malpractice claims, and a documented informed-consent process is a standard defense element.

The Texas Medical Board's rules on non-FDA-approved treatments do not prohibit prescribing investigational compounds, but they do require that the physician's medical record reflect the clinical rationale and patient consent. Physicians who prescribe BPC-157 without that documentation carry elevated liability exposure.